aa 8-2會期部長業務報告-書面報告.pdf
TRANSCRIPT
-
1
8 2
() 1. 71
(100) 59 4 9 6 144 2 ( 10 3)
2. 101 3 23
3. 71
-
2
4. 101 72
5. 71 5 14
6. 5
() 1. 101 9 6 195
13 182 101 5 (122 )(58)(1 ) (1 )
2.
-
3
3. 101
4. 101 3 20 21
5. 101 5 11101 1 6
6. 101 4 5 8 2,490
-
4
() 1. 94-100
35.6%
2. (DOTS)101 6 6,890 90%
3. X 101 62,855 2,031 99 1,797
4. (MDR) 96 5 100101 6 78
5.
() 1. 101 6 2
3,081 101
-
5
1,062 795 74.9%15-24 296 28.8
2.
3. 4
4. 1011640,275
5. 96 101 46 101 6 7,960
-
6
6. 101 6
21 () 928 415 1 101 1 6 23 2,480 311 90%
() 1. 100 266 7,665
100101101630258.2 97.86 101 297 5,365 101 10 1 65 6 6 102 1 1 50-64
2. 10-15% 100 12 1 101 3 31
-
7
3. 101 1 1 6 30 25 / 7
4. 101 101 8 16 1,247
5. 101 3 1 101 A/H5N1 8 10 9,561
() 1. 101
101 493 5 157
-
8
6 111 (70.7%) 2.
WHO 555 5 ( 5 )
3. ()
4. (Enterobacteriaceae)
5. 101 59 9
()
-
9
1. /
2. 101 4 9 MMR Tdap-IPV
3. 101 5 PCV 4.3 102 2-5 PCV
4. 75
() 1.
100 9 16
1
-
10
2
3 63 50
4
2. 98 101 6 189 19 81 24 57 112 101 9 101
3.
1 9 17 24
2 13 8
-
11
3
15 21 28 24
() 1.
99 7 1101 79203 530
2. 101 39 1311
3. 14 101 6
-
12
131 1 3,322 4.
101 16 45 103 1 1
5. 101 10
() 1. 101 14
19,179 5
2. 109 104 96 1 4,131 100 3 6,628 94 71.5% 100 5%
3.
-
13
/100 6.51 16.54
() 1.
101 22 292 101 6 126,271 188,605 1.52 44.21%
2. 97 7 499 1,696 95%100 1,211 96.12%101 6 657 96.65%99 27 100%100 40 97.5%101 101 6 35 88.57%
-
14
3. 100 3,507 1015.1954,406 19.3 899 20.4% 13 2 99 11 100 12
() 1. 101
101 505 238 7 14
2. 101 193 6 5
3. /98 58
4. 1 10
-
15
2 3
() 1. 5 (33
2510026) 11
2. 101 1 1 103 12 31 200
-
16
3. 100
4.
5. () 1
24 98.7
2 () ()
6. 45
4 5 4 6 5 10
-
17
1 2
3 4 5 6 1
2
3 4 103 5 6 7 8
9 10
-
18
1 102 1 49 22 55% 10
2 101 4
3 () 100 200 101 7 9 101 9 11 101 9 1
4 100 11 1 101 6 22
5 101 7-9
-
19
6
7 skill mix
8 101 8 21 9 26
7. 1 101 7 10
() 101
2 2/3( 60 100 ) 101
3 1012
-
20
120 6 720
8. 1 101 6 46
2 95 100
2,918 ( 1,450 1,468 )
3 100 69 2,488 101 80
4 100 101 101 6 30 747 358 41 12 )9 9 911 440 4312 416
9. 1 101 7
16
-
21
101 8 317 10
2 102 102
() 1.
2.
1 25
2 101 7 97 6 65 (56711) 11 21 ()
-
22
3. 24 95 3 101 8 3,484,795
4. 15 ( 25 ) CDC 61%
5. 1 101 ()
9102 2 100 81 10,038 1,288 150
2 101 3 101 ()
11 100 3,286 1,53011,048
4 101 102 16
5 2,000 ( 1,497 227 216 3)
-
23
6. ( 12 100 1 101 8 64,528 )
7. () () () ()
() 1. 1
100 12 274
2 100 12 208
3 100 12 150
2. 100 12 IC 32
-
24
3. 101 6 189 175
() 1. 1
HIS 100 48 ( 30 18 )101 7
2 32 ( 23 9)(PACS)
3 100 19 101 1-8 4,623
4
-
25
2.
1 101 1 8315 3
2 101 1 8 314 241 2 40
3. 101 86 1 8 2 9,815 9,535 30,809 1 4,821 875 3 9,579 3,200
4.
5.
-
26
101 40 26 9 1600
6. 100 776 101 31( 27)
7. 24 101 1 8 201 94.37% 101
8.
9.
-
27
1 8 29
2 8 29 2 8 30 1
3 8 31 8 31 IDS 9 3
4
5 3,550
() 1. 1
2
(22 )(63 )(368 )
-
28
3
5 2. 1
99 100 1 130 25 2 157
99 100 4,55099 100 5,117 9667
2 ()101 8 100 101 13
3. 1
97 2.3%98 5.7%99 16.3%100 21% 101 8 22%
-
29
100 61,675 97 3.5 101 8 37,622 100 61%
9,443 101 CDR
2 100 100 30 101
4. 7 7 8 7 8 1 2 101 2 23 7 12 9 6 95
5.
-
30
1 99 35 2.98%100 ( 1 )100 11
2 ()()
3 100 4 101
-
31
4 101 7 102 7
5
6 98 9 101 6 94 266
() 1. 99 4 1
99 3 604 101 6 95
2. ()
-
32
101 6 6.93
3. 101 6 306 1.19%
4. 7 100 12 1
() 1. 1 100
4.39 4.17 5.01% 4 5,511 4 5,366
-
33
145 0.32% 2 101 1 5
4.42 4.14 6.33%45,95345,264 689 1.50%
3
2. 1 100 7 1 7
15 101 1 17 61611
2
3. 1 101
21.47 101 6 20
-
34
57114C 6 43 12.83
0.572 8.527 9% 4 2 6 3%9.099
101 1 1
2 101 3.2
3 1008RBRVS 37 100 9 100 10 24 101 6 28
-
35
101 9 101 12
4. (1)(2)(3) 3 101 6 384.3
() 1.
101 6 280 110
2. 1 101 6
1,927 1.15 7 17.48 1,518 1,165
2 101 101 6 1.37 3.18
-
36
3. 10162,019 5,692
4. 1
101 6 42.1 18
17.8 17
7.3
2 37
5. (IDS) 48 (40 )
-
37
101 25 4-6 (100 4.39 )
() 1.
90 99 150 () 100 () 5.7 99 100 32,468 100 12 17 166.2
2.
3. 98 12 101 193
-
38
46 100 0.15 12.5%
() 1. 100
1 4 100 1 26 1 2
2.
1
2
-
39
3 101 6
4
5 1 1
6 101 8 13 2348 ( 118 )
() 1. 101 1 6 212
18 1,102 111
2. 101 2 6 4
-
40
30 1,510 734 609 51 47 47 10 12 16 2 1 1.3%
3. 61 612
4. 101 7 9 102 4LC/MS/MS
5. 101 1 6 27
() 1. 1 101 8 8 11
17 1 31
-
41
2 101 1 6 167 )7773
2. 1 101 6
21 5,220 2 101 6
224 3
101 QSA 9 63.31%101 6 5,521 714 685 17 () 101 3 20 100 7 1 424
-
42
5 101 6 8,375 97.7%
3. 1
http://fadenbook.fda.gov.tw/101 8 13 435 8,628 101 4 400
2 101 6 28 101 7 9
-
43
4. 1 101 8 9
8 15
2 101 9 6 101 9 12 101 9 20
3 101 7 21 () () 8 2
()
-
44
1. (cGMP) 101 6 160 ( 10 3 ) 20 ( 151 ) GMP 40 PIC/S GMP
2. 101 6 685 97 64 3 30 98 64330 10 73 480
3. 184 4 5
4. 101 6 52
5. 101 644927
6. 6
7. 101 6 27 GMP GMP
-
45
8. 101 4 26 3
9. 101 5 30
10. GMP 16 GMP
11. 20 309 4 PCNB 98.71%
12. 101 8 1 10
13. Wnt 1 2
14. 101 6
-
46
15. 4 14 5 5 35 4 14 11 30 10
() 1.
101 6 18 4
2. (REMS)
3. 101 4 5 (REMS) 101 7 REMS 9 12 4 58
4. 4
5.
-
47
22 14 31 4 9
6. 71
() 1.
101 6 9,575 83 0.87%
2. 101 6 8,644 100 8,218 5.2%
() 1. 101 6
4,080 1,707.6 99 1 13.9% 101 6 4.08%
2. 99 3 99 1 3 190 216
-
48
43 149 21.9% 18.4 %
()
101 6 481 100 3 3 96 101 6 6 6
() 1. 101100
186 94.04% 1 98.35%101 1-5 85 96.35% 99 100 101 4 15 101 1 6 2 8,485
-
49
2. 101 1 6 2 7,977 768 10 6,842 1,875 4,205 1,674
3. 101 1 6 5,688 340 6,579
4. 100 158 71.4%99 67.2% 100 45.6% (93 24%97 35.1% 2025 50%) 99 11 24 100 5 11 101 6 1,659 99.8%
5.
-
50
28 4 1 10 50 99 1.090 100 1.079 101 1-6 1.07816 1.130 18 101 6 101 942 198 293 491 52.12%(491/942)
6. 101 6 193 78 40 101 6 3,560 20
-
51
101 6 36 9 4,000 101 1-6 291 5 50 100 100 11 101 6 82 244
() 1. 4 5
100 1 12 35 2,375 97.4% 98%
2. 99 100 47 101 3 15 101 1 6 5 6,694 1003417 9,898 91.38% 97%
3. 5 1 100 30 9,118 101 22 2,659 146
4. 7 7
-
52
99 103 1 1 98.3%100 100 80%100 1 1 98%101 1-5 46 7 84.2% 100
5. 22 1 6 14 2 4 45
6. 132 748 383 6,506 13 154
-
53
22,475 101
7. 100 2,954101 101 6 6,598
8. e1003973510116139,679 3,045 31 Teens 9 1,981 19 87 113 2 6,264 62 51 414 msn 217
-
54
() 1. 40 64 3 155
65 1101 1 6 112 (100 16)109
2. 100 3 103 6 166 14 416 582
3. 100 18 62.3% 44.6%
4. 100 20 22 7 5 3,843 2 3,958 3 6,418 90%
5. 101 Healthy Lifestyle Healthy Blood Pressure 1,014 887
-
55
1,987
6. 100-104101-103
7.
8. 100 536 1,400
9. 483100 174 101 186 22
10. 100 126 50 33
-
56
2,881 12 5,305 65
11. 100 9 65 81 101 1 6 50 69 29.8 50-69 62.3 65 269 101 1 5 2,504
12. 100 1,333 477 26%99 100 60%101 622 371 1,333 253 770 80%
-
57
13. 99 100 100 12 13 101 6 21101 40 101 101 4 11 20 WHO Working Group on HPH and Age-Friendly Health Care
14. WHO-100 9 20 101 20
-
58
APEC101 8 28-29 2012 APEC
15. 100 12 229293 424101 6 22 749 3292 101 12 5
() 1.
Alliance For Healthy Cities, AFHC 101 6
-
59
8 11 AFHC2 30 2 34
2. 1 101 6 76 WHO
2 100 12 Health Care Without HarmHCWHThe First Global Climate and Health Summit HCWH UNFCCC 17 17 Climate Change and Public Health: Healthy Climate, Healthy People, Healthy Economy WHO TF on HPH and Environment WHO The First Global
-
60
Climate and Health Summit 3 100 WHO-HPH Recognition
Project 15101 6
4 101 4 11-13 20
5 101 21 125 ()46 4039
3. 1 101 18 142
( 38.6 5
2 100 13
-
61
4. 94 101 28 101 6 19
5. 100 12 7,411 303
6. 1 3,699
101 6 293
2
-
62
101 6 46
7. 1 101 6
9,345
2 100
8. 100 100 1 1,172 70 604(39.84%)126
() 1. 22
101 60 600 22
-
63
101 6 3,310 30 8,000 187
2. 368
3. 0800-367-100101 -
4. 1 18 99
-
64
64.1% 100 65.1%
2 100 22 1035 138 101
3
5. 1
2 101 18 143
()
-
65
1. 100 99 19.8% 19.1% 99 9.1% 8.2%
2. 101 1 6 34 6,416 2,995 2,939 253 8,000
3. 101
4. 101 113 2012 65
5. 101 5 (DG SANCO) Ms. Paola Testori Coggi 37 1
6. 101 3 1 200
-
66
101 6 2,054 96%
7. 101 1 6 4 2,8282012 3 1,067
8. 98 6 4 101 1 6 96 2,551
() 1.
18 96 17.2% 100 11.3%
2. 97 174.4 100 173.7 0.4% 97 10 94.4 100 93.4 1.1% 105 10%
3. 92 96 41% 94 98 43% 2% 58% 60% 2%
4. 101
-
67
1 6 279 122.7 38.6 62.3 55.4 2,357 5,836 1,456 868 12,157 664 1,843
5. 101 1 1 3 1 3HPV101 3 22 6 30 1 2,034 2 2,026 1 1,354 2 1,340
6. 222 69
7. 97 100 39 8
-
68
101 37 8. 69 101
1 5 8,000 99 1 42% 98 39% 3%
() 1.
101 6 646 30
2. 5 1 4
3. 8 101 6 48 78 17
() 1. DBPR108
-
69
101 1 FDA 7
2. DBPR104 99 7 30 11 23 FDA
3. 5-MTP50%
4. 71 101 2 1 2
5. -
-
70
CKD2011 10 CKD
6. B 101 4
7. respiratory syncytial virus, RSV RSV
8.
-
71
Sun1 Sun1 2.5
9.
10.
() 1.
65 (Toward Universal Coverage)
-
72
WHA (2005) 1610 101 5 24 DG SANCO(WMA)(WHPA)
2. APEC(2011 2012)APEC (HWG)(Health Policy Dialogue) 2012 APEC (APEC High-Level Meeting on Health and the Economy)(A Life Course Approach to Reducing the Economic Burden of Disease)Johnson & Johnson
3. APEC
-
73
(Workshop on Cost-effectiveness of Strategies for Human Security) APEC 101 8
4. 2011 25 40 2012 101 11 14 16
() 1. 101
12
2. Non-communicable Disesses-Global priorities and solutions
3. (1) 101 8 7
-
74
(2) (TaiwanIHA)(AMDA)1008 130 130 101 2 1
(3)
4. 100 6 26
-
75
101 8 1
SARS
5. (1) ()
e-Health (2)
(3) 101 8 179
() 1. 100
23 146
-
76
101 8 8 50
2. 100 13
() 101 8 52
699
101/2/15 Mr. Bruce Atkinson 5
101/3/01 Pham Van Thuc 6
101/3/20 Mr. Melinda Pavey 5
101/4/9-10 Esperanza Martinez 2
101/4/30 Dr. Jewel Mullen 7
101/5/1 Hon. Jenniffer A. Gonzalez-Colon 6
101/7/25 Excmo. Lic. Gudy Rivera Estrada 7
101/7/27 Dr. Douglas Slater
-
77
Mr. Andreas Wickham 2
(101.0108)
262 50 300 61 19 6 1 52 699
() 1. 1
2 3 4 2. 1
-
78
2
3 4 5
() 1. 22 102
2. 3. 1 2 3 4
() 1. 1 2 3
-
79
2. 1 101
2 3. 1 2
2
3 4
() 1. 2. 55 64 3.
4. 5.
6.
HPV 7.
-
80
() 1. 2. CDC 3. 4. Gastein European Health Forum
()
()
()
-
81
() 96 98 100
() 1.
2.
3. 4.
() 2143
-
82
1670
() 1.
2. 3. 4. 5.
()
() 1.
2.
-
83
IDS
3. (101-105 )
4.
() 1.
2. 101
() 1. 99 4 1
2.
-
84
() 1.
6 ()
2. 36
() DRG
1. DRG
2.
-
85
()
() 102 1 1 6
() 1.
101 3 6 25 7 19
-
86
2.
3.
10-15 4.
()
() 1. 2. 3.
4.
100%
() 1. 71
-
87
2. 71
()
()
() 103-104 PCV
()
-
88
()
() MIT
()
-
89
()
1.
2.
()
()
()
()
-
90
1.
2. 290
3.
4. 101 6
5. 100 101 102 101 102
()
-
91
()
101
()
() ()
()
()
()
()
-
92
()
()
()
() () () () ()